Shares of Immune Pharmaceuticals Inc (NASDAQ:IMNP) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Brokerages have set a 12 month consensus price objective of $2.00 for the company, according to Zacks. Zacks has also given Immune Pharmaceuticals an industry rank of 101 out of 255 based on the ratings given to related companies.
Several research analysts have commented on the company. ValuEngine upgraded Immune Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Maxim Group downgraded Immune Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 6th.
Immune Pharmaceuticals remained flat at $$0.16 during trading on Tuesday, according to Marketbeat Ratings. The company’s stock had a trading volume of 37,176 shares, compared to its average volume of 1,024,053. Immune Pharmaceuticals has a one year low of $0.06 and a one year high of $2.64. The company has a current ratio of 0.31, a quick ratio of 0.31 and a debt-to-equity ratio of 0.15.
Immune Pharmaceuticals (NASDAQ:IMNP) last released its quarterly earnings data on Tuesday, May 15th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.05.
About Immune Pharmaceuticals
Immune Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis.
Further Reading: How to Use the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.